We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Impact of 131 I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma †.
- Authors
Park, Hyun Jin; Choi, Jung Yoon; Kim, Bo Kyung; Hong, Kyung Taek; Kim, Hyun-Young; Kim, Il Han; Cheon, Gi Jeong; Cheon, Jung-Eun; Park, Sung-Hye; Kang, Hyoung Jin
- Abstract
Background: The optimal conditioning regimen of tandem high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NBL) has not been established. The efficacy of 131I-MIBG therapy is under exploration in newly diagnosed HR-NBL patients. Here, we compared the outcomes of tandem HDC/ASCT between the 131I-MIBG combination and non-MIBG groups. Methods: We retrospectively analyzed the clinical data of 33 HR-NBL patients who underwent tandem HDC/ASCT between 2007 and 2021 at the Seoul National University Children's Hospital. Results: The median age at diagnosis was 3.6 years. 131I-MIBG was administered to 13 (39.4%) of the patients. Thirty patients (90.9%) received maintenance therapy after tandem HDC/ASCT, twenty-two were treated with isotretinoin ± interleukin-2, and eight received salvage chemotherapy. The five-year overall survival (OS) and event-free survival (EFS) rates of all patients were 80.4% and 69.4%, respectively. Comparing the 131I-MIBG combined group and other groups, the five-year OS rates were 82.1% and 79.7% (p = 0.655), and the five-year EFS rates were 69.2% and 69.6% (p = 0.922), respectively. Among the adverse effects of grade 3 or 4, the incidence of liver enzyme elevation was significantly higher in the non-131I-MIBG group. Conclusions: Although tandem HDC/ASCT showed promising outcomes, the 131I-MIBG combination did not improve survival rates.
- Subjects
SOUTH Korea; STEM cell transplantation; ENZYME analysis; BENZENE derivatives; ETOPOSIDE; NEUROBLASTOMA; CARBOPLATIN; TOPOTECAN; CANCER chemotherapy; CHILDREN'S hospitals; ISOTRETINOIN; INTERLEUKIN-2; HEALTH outcome assessment; RETROSPECTIVE studies; ANTINEOPLASTIC agents; IFOSFAMIDE; MANN Whitney U Test; FISHER exact test; AUTOGRAFTS; IODINE radioisotopes; T-test (Statistics); DESCRIPTIVE statistics; FLUORESCENCE in situ hybridization; CISPLATIN; CYCLOPHOSPHAMIDE; CHI-squared test; KAPLAN-Meier estimator; RESEARCH funding; SALVAGE therapy; PROGRESSION-free survival; OVERALL survival; DISEASE risk factors; EVALUATION
- Publication
Children, 2023, Vol 10, Issue 12, p1936
- ISSN
2227-9067
- Publication type
Article
- DOI
10.3390/children10121936